We are excited to share our paper on Pilot clinical study showing abnormal copper metabolism in healthy Wilson disease heterozygote subjects, accepted to CTSJournal.
See it here : https://lnkd.in/e-rzZnXp #ASCPTJournalFamily – Wilson Disease Association
64Cu has been used for decades to study WD, however clear data are lacking to document the rate of fecal elimination of 64Cu in WD heterozygotes (WD HTZ). This pilot study showed that the cumulative fecal excretion of 64Cu, upon iv dosing of [64Cu]CuCl2, is about 3.8 times lower in WB HTZ subjects as compared to healthy subjects. Also, lower plasma 64Cu concentrations were measured in this population. These results might contribute to develop a gene-based therapy for WD patients. Thanks to all Vivet Therapeutics team for their commitment to improve disease understanding for gene therapy outcomes
